← 返回

肿瘤细胞内在的 BIN1 缺失通过 G3BP1 介导的 STAT1 降解促进非小细胞肺癌的免疫抑制并阻碍铁死亡

英文原题:Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1.

查看英文原题

Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1.

PubMed 2025/05/09(内容时间) J Exp Clin Cancer Res Q1 · IF 14.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究强调了 BIN1/G3BP1/STAT1/CD8+TIL(肿瘤浸润淋巴细胞)信号通路在 NSCLC 进展及其免疫逃逸机制中的关键作用。这些发现为开发靶向 BIN1 的疗法奠定了基础,旨在提高肿瘤免疫原性,并将免疫“冷”NSCLC 转化为更易响应的疾病。

研究思路结论见上方概要

肿瘤常通过限制T细胞浸润来逃避免疫监视。在非小细胞肺癌(NSCLC)中,CD8+ T细胞浸润增加与免疫治疗的良好反应相关。尽管BIN1被认为是抑癌基因,但其在塑造NSCLC肿瘤微环境中的作用尚未完全阐明。

为探究BIN1表达与NSCLC中CD8+T细胞浸润之间的关系,我们利用NSCLC患者的临床信息进行了全面的数据分析。评估了NSCLC组织中BIN1的表达水平,并检测了其与CD8+T细胞浸润及患者生存结局的相关性。在同基因NSCLC小鼠模型中应用了靶向BIN1的功能缺失策略,以评估其功能意义。监测了肿瘤生长,并通过质谱流式细胞术和流式细胞术技术分析了免疫细胞群体的频率和功能。使用多重检测分析了细胞因子分泌谱。此外,采用RNA测序、免疫沉淀-质谱联用和分子对接来确认BIN1与细胞因子编码基因之间的直接相互作用。最后,利用代谢组学分析、ROS测定和MDA检测探索了BIN1在NSCLC细胞铁死亡中的调控作用。

我们观察到BIN1在NSCLC肿瘤组织中的表达下调,其表达降低与疾病进展晚期和不良预后密切相关。对人NSCLC样本中免疫浸润的生物信息学分析显示,NSCLC组织中BIN1表达与CD8 + T细胞浸润呈正相关。此外,BIN1对NSCLC患者的预后影响与CD8 + T细胞浸润水平密切相关。在同系小鼠模型中,敲除NSCLC细胞中的BIN1显著抑制了CD8 + T细胞浸润并损害了其细胞毒性功能,促进了肿瘤免疫逃逸。在机制上,我们证明BIN1直接与G3BP1相互作用,其敲除可稳定G3BP1。这进而促进STAT1降解并减少T细胞招募趋化因子如CXCL10和CCL5的分泌。最后,我们的发现揭示BIN1通过G3BP1/STAT1/GSH通路影响NSCLC细胞中的铁死亡,从而调控NSCLC细胞增殖、迁移和侵袭。

展开英文摘要原文

Tumors often evade immune surveillance by limiting T cell infiltration. In non-small cell lung cancer (NSCLC), increased infiltration of CD8 + T cells is associated with a favorable response to immunotherapy. While BIN1 is recognized as a tumor suppressor gene, its role in shaping the tumor microenvironment in NSCLC has yet to be fully clarified.

To investigate the relationship between BIN1 expression and CD8 + T cell infiltration in NSCLC, we performed a comprehensive data analysis utilizing clinical information from NSCLC patients. BIN1 expression levels in NSCLC tissues were evaluated, and their correlation with CD8 + T cells infiltration and patient survival outcomes was examined. Loss-of-function strategies targeting BIN1 were applied in syngeneic NSCLC mouse models to assess its functional significance. Tumor growth was monitored, and immune cell populations were analyzed in terms of frequency and functionality through mass cytometry and flow cytometry techniques. Cytokine secretion was profiled using multiplex assays. Additionally, RNA sequencing, immunoprecipitation-mass spectrometry, and molecular docking were employed to confirm direct interactions between BIN1 and cytokine-encoding genes. Finally, the regulatory role of BIN1 in ferroptosis in NSCLC cells were explored using metabolomics analysis, ROS measurement, and MDA detection.

We observed that BIN1 expression is downregulated in NSCLC tumor tissues, with its reduced expression strongly associated with advanced disease progression and poor prognosis. Bioinformatics analysis of immune infiltration in human NSCLC samples revealed a positive correlation between BIN1 expression in NSCLC tissues and CD8 + T cell infiltration. Furthermore, the prognostic impact of BIN1 on NSCLC patients is strongly linked to the level of CD8 + T cell infiltration. In syngeneic mouse models, the knockout of BIN1 in NSCLC cells significantly inhibited CD8 + T cell infiltration and impaired their cytotoxic function, facilitating tumor immune evasion. Mechanistically, we demonstrated that BIN1 directly interacts with G3BP1, and its knockout stabilizes G3BP1. This, in turn, promotes STAT1 degradation and reduces the secretion of T cell-recruiting chemokines such as CXCL10 and CCL5. Finally, our findings reveal that BIN1 influences ferroptosis in NSCLC cells through the G3BP1/STAT1/GSH pathway, thereby regulating NSCLC cell proliferation, migration, and invasion.

This study highlights the crucial role of the BIN1/G3BP1/STAT1/CD8 + tumor-infiltrating lymphocyte signaling pathway in the progression of NSCLC and its mechanisms of immune evasion. This fundings lay a foundation for the development of BIN1-targeted therapies aimed at improving tumor immunogenicity and transforming immunologically "cold" NSCLC into a more responsive disease.

论文信息

作者
Wang J、Jia Y、Liu T、Liu X、Yin S、Chen J、Xu X、Zhang Y
第一作者单位
Department of Tumor Immunotherapy, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, 050035, P.R. China.China
通讯作者单位
Department of Tumor Immunotherapy, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, 050035, P.R. China. cdlihualiu@hebmu.edu.cn.China
期刊
Journal of experimental & clinical cancer research : CR2025 May 9
原文标识
PubMed 40346580 · DOI 10.1186/s13046-025-03404-9